Literature DB >> 11453813

Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.

M H Tan1, M Gordon, O Lebwohl, J George, M G Lebwohl.   

Abstract

BACKGROUND: Infliximab is an anti-tumor necrosis factor alpha monoclonal antibody IgG effective in the treatment and maintenance of remission of active refractory Crohn disease and associated draining enterocutaneous fistulae. Multiple infusions of infliximab show promising results in patients with rheumatoid arthritis. Currently, there is limited clinical experience with infliximab, and no published reports exist on its use in cutaneous disorders. OBSERVATIONS: We describe 2 patients with Crohn disease and pyoderma gangrenosum and 1 patient with Crohn disease and psoriasis who were treated with infliximab for recalcitrant Crohn fistulae, with concurrent improvement in their skin diseases.
CONCLUSIONS: These cases suggest that infliximab, a promising therapeutic agent for refractory Crohn disease and fistulae, may also be effective in the treatment of pyoderma gangrenosum and psoriasis associated with Crohn disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453813

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  16 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

3.  Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.

Authors:  K Vandevyvere; F P Luyten; P Verschueren; R Lories; S Segaert; R Westhovens
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

Review 4.  Biological therapy for dermatological manifestations of inflammatory bowel disease.

Authors:  Maddalena Zippi; Roberta Pica; Daniela De Nitto; Paolo Paoluzi
Journal:  World J Clin Cases       Date:  2013-05-16       Impact factor: 1.337

5.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 6.  Pyoderma gangrenosum-a novel approach?

Authors:  Anastasia Atanasova Chokoeva; José Carlos Cardoso; Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2016-07-05

Review 7.  Important cutaneous manifestations of inflammatory bowel disease.

Authors:  L B Trost; J K McDonnell
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

8.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 9.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

10.  Infliximab as a therapy for non-Crohn's enterocutaneous fistulae.

Authors:  Ravindra S Date; Kanwar Jit Singh Panesar; Paul Neilly
Journal:  Int J Colorectal Dis       Date:  2004-06-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.